IMPORTANCE Staphylococcus aureus bacteremia is common and frequently associated with poor outcomes. Evidence indicates that specific care processes are associated with improved outcomes for patients with S aureus bacteremia, including appropriate antibiotic prescribing, use of echocardiography to identify endocarditis, and consultation with infectious diseases (ID) specialists. Whether use of these care processes has increased in routine care for S aureus bacteremia or whether use of these processes has led to large-scale improvements in survival is unknown.
S taphylococcus aureus bacteremia (SAB) is common and frequently associated with poor outcomes. The estimated annual incidence of SAB in the United States and Europe is 5 to 40 cases per 100 000 population and has been increasing in recent decades because of increasing exposure to health care. [1] [2] [3] [4] The SAB case fatality rate in the preantibiotic era was 80% and has improved to 20% to 30% in previous reports. [4] [5] [6] Largely observational evidence indicates that specific care processes are associated with improved outcomes for patients with SAB, including early source control, 7,8 use of echocardiography to identify endocarditis, 7,9 appropriate antibiotic prescribing, 8, 10 and consultation with infectious diseases (ID) specialists to guide management. 11,12 Treatment guidelines and published expert opinions call for increased use of these evidence-based care processes for patients with SAB. 4, 7, 8, 13, 14 However, whether there have been widespread increases in use of these evidence-based care processes for patients with SAB or whether use of these processes has led to large-scale decreases in SAB-associated mortality is unknown. Large studies of SAB outcomes have previously been difficult to perform in part because the administrative claims data typically used to perform outcomes studies do not accurately identify patients with SAB, [15] [16] [17] and few large health care databases have included microbiology results. The Veterans Health Administration (VHA), the largest integrated health care system in the United States, has recently aggregated microbiology results nationally. We examined national VHA microbiology data and other clinical and administrative data to explore trends in the use of evidence-based care processes and mortality among patients with SAB in 124 hospitals between 2003 and 2014. Our aim was to estimate the extent to which increasing use of evidence-based care processes may have contributed to improving survival among patients with SAB.
Methods
The institutional review board of the University of Iowa and the Research & Development Committee of the Iowa City Veterans Affairs Health Care System approved this study and waived informed consent for this retrospective cohort. All data were deidentified.
Study Population and Data Source
We conducted a retrospective observational cohort study of all patients with a blood culture positive for S aureus during admission to acute care units at 124 VHA hospitals in the 48 continental United States, the District of Columbia, and Puerto Rico from January 1, 2003, through December 31, 2014. We obtained data through the Veterans Affairs Informatics and Computing Infrastructure, which includes data extracted from VHA's integrated electronic medical record. The methods used to extract microbiology results from electronic medical records have been described previously. 18 We also extracted antimicrobial susceptibility data to classify isolates as methicillin-resistant S aureus (MRSA) or methicillin-susceptible S aureus (MSSA). If a patient had more than 1 episode of SAB during the study period, we included only the first episode in the analysis.
Outcomes
Our primary outcome measure was all-cause 30-day mortality after the first blood culture positive for S aureus. Dates of death were obtained from the VHA Vital Status File, which combines mortality information from multiple VHA and non-VHA sources and tracks patients even if they leave the VHA system. The Vital Status File has excellent agreement with the National Death Index.
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Variable Definitions
For each patient, we defined time of bacteremia onset as the time of the first sample obtainment for which the blood culture result was positive and classified places of acquisition as community acquired (CA), health care associated (HCA), or hospital onset (HO) according to previously published definitions. 20, 21 The episode was considered to be HO bacteremia when the patient had been in the hospital for 48 hours or longer at the time of the first positive blood culture result. Among episodes that did not meet the criteria for HO bacteremia, HCA bacteremia was defined based on the following: (1) admission to an acute care facility within 90 days before the bacteremia episode, (2) residence in a nursing home or rehabilitation facility, (3) receipt of renal replacement therapy, or (4) receipt of wound care or specialized nursing care in an outpatient setting or at home in the 30 days before the onset of bacteremia. If the patient did not meet any of the above criteria, the episode was classified as CA bacteremia. Additional patient characteristics were identified using diagnosis codes, laboratory tests, and vital signs. Specifically, laboratory test results and vital signs within 24 hours before and after the first positive blood culture result were collected for each patient and categorized according to previously described methods. 22 Comorbidities were assessed using diagnosis codes based on the methods of Elixhauser et al 23 and the algorithm proposed by Quan et al. 24 Patient-level data were complete for all patients with the exception of vital signs, body mass index, and laboratory values. These data were missing in less than 8% of patients with the exception of serum albumin (missing in 31.8%) and bilirubin levels (missing in 31.3%). Information pertaining to antimicrobial administration, echocardiography use, and ID consultation for each patient was extracted from the Veterans Affairs Informatics and Computing Infrastructure to create a series of care quality process measures. We defined appropriate antimicrobial therapy as any administration of recommended intravenous antimicrobial therapy (ie, vancomycin or daptomycin for MRSA or penicillinase-resistant penicillins or first-generation cephalosporins for MSSA) between the first positive blood culture result and discharge. 8, 13, 14, 25 We defined echocardiography use as completion of echocardiography (transthoracic or transesophageal echocardiography) between the first positive blood culture result and discharge and ID consultation as a completed consultation order or documentation from ID consultation services in the electronic medical records between the first positive blood culture result and discharge. We manually reviewed titles of consultation orders and inpatient notes to identify ID consultations. Specific details of findings and recommendations from ID consultation notes and echocardiography reports were not available.
Statistical Analysis
First, we compared characteristics of patients across the number of evidence-based care processes received using χ 2 tests for categorical measures and 1-way analysis of variance or Kruskal-Wallis tests for continuous measures. We used Markov chain Monte Carlo imputation to estimate values for missing variables. Crude mortality rates and use rates for each evidence-based care process (ie, appropriate antibiotic therapy, echocardiography use, and ID consultation) were summarized by year, and statistical significance of trends were assessed using Cochrane-Armitage test for trend. Second, we fit a patient-level, multivariable logistic regression model to predict all-cause 30-day mortality while carefully avoiding overfitting. Patient characteristics were considered to be candidate variables for the risk adjustment model if they were possibly related (P < .25) to mortality in bivariable analyses and missingness before imputation was less than 10%. This model included a random intercept for hospitals to account for the grouping of patients within hospitals. Detailed description of the model-building process is available in the eMethods in the Supplement. The risk adjustment model for 30-day mortality included patient age, body mass index, place of bacteremia acquisition, methicillin susceptibility of the Saureusisolate, 13 comorbidities, 4 vital signs, and 5 laboratory results. The model had excellent discrimination with a C statistic of 0.809. 26 Model validation revealed nearly identical receiver operating characteristic curves for the training and validation data sets (eFigure 1 in the Supplement), which suggests good prediction capability without overfitting. We used this risk adjustment model to assess trends in riskstandardized 30-day mortality rates over time. We assessed patient-level associations between receipt of individual evidence-based care processes and mortality by adding variables that indicated patients who received each of the 3 care processes to the risk adjustment model one at a time. We then included all 3 care processes in 1 model simultaneously after assessing possible collinearity between care processes using φ statistics for correlations between variables and variance inflation factors. Models for associations between receipt of care processes and mortality also included cohort year as a series of fixed effects. In addition, we created indicator variables for all possible combinations of care processes that a patient could receive and determined associations between mortality and each of the 8 possible combinations of care processes. This method allowed us to assess associations between mortality and receipt of specific combinations of care processes. We also evaluated for potential differential effects over time using stratified analyses that split the cohort into four 3-year periods (2003-2005, 2006-2008, 2009-2011, and 2012-2014) .
In addition, we conducted subgroup analyses for MSSA, MRSA, and place of acquisition to determine whether mortality trends and associations with care processes were stable across subgroups. Because patients who died early might not have had time to receive evidence-based care processes, we performed sensitivity analyses for associations between care processes and mortality, excluding patients who did not survive 2 or more days after the onset of bacteremia.
Finally, we used the method of recycled predictions as described in the eMethods in the Supplement to compute the marginal effects of increases in the number of care processes on mortality to estimate the fraction of the change in mortality that may be attributed to changing use of care processes over time. 27, 28 All hypothesis tests were 2-sided, with a significance level of P < .05. Statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc). Table 1 summarizes the patient characteristics. Approximately half of patients with SAB had HCA bacteremia (19 271 [52.3%]), whereas 8253 (22.4%) had CA bacteremia and 9344 (25.3%) had HO bacteremia. The median number of Elixhauser comorbidities was 8 (interquartile range, 5-10), with 34 324 patients (93.1%) having at least 1 cardiopulmonary comorbidity, 11 392 (30.9%) with malignant tumors, and 23 411 (63.5%) with at least 1 mental health comorbidity. Table 2 summarizes the model used for patient-level risk adjustments. Risk-adjusted mortality decreased from 23.5% (95% CI, 23.3%-23.8%) in 2003 to 18.2% (95% CI, 17.9%-18.5%) in 2014 ( Figure 1 ). Similar mortality trends were observed for MRSA, MSSA, and all places of acquisition (ie, HCA, HO, and CA) (eFigure 2 and eFigure 3 in the Supplement).
Results
Study Population
Trends in Use of Evidence-Based Care Processes and Association With Mortality Trends
Overall, 19 608 patients (53.2%) with SAB had ID consultation during the index hospital stay. The number of patients with ID consultation increased from 1390 (37.4%) in 2003 to 1717 a Included in the model because of significant interaction with serum creatinine level.
Association The use of echocardiography, ID consultation, and appropriate therapy were associated with lower 30-day mortality after adjustment for patient characteristics and other care processes, with risk-adjusted odds ratios (ORs) of 0.74 (95% CI, 0.68-0.79) for appropriate antibiotics, 0.73 (95% CI, 0.68-0.78) for echocardiography, and 0.61 (95% CI, 0.56-0.65) for ID consultation (Figure 3 ). In addition, there was a dose-response relationship between the number of evidence-based care processes that a patient received and mortality (Figure 3) , which occurred regardless of the specific combinations of care processes received. The riskadjusted OR for mortality was 0.33 (95% CI, 0.30-0.37) for patients receiving all 3 care processes compared with patients receiving no process.
Appropriate antibiotic therapy was associated with lower 30-day mortality in subgroup analyses of patients infected with MRSA (risk-adjusted OR, 0.53; 95% CI, 0.48-0.59) and those infected with MSSA (risk-adjusted OR, 0.57; 95% CI, 0.52-0.63) (eFigure 6 and eFigure 7 in the Supplement). The association between receipt of care processes and mortality was generally stable across cohort years and by place of bacteremia onset (eFigure 8 and eFigure 9 in the Supplement). Sensitivity analyses with elimination of patients who did not survive for 2 or more calendar days after blood culture was performed also demonstrated associations between evidencebased care processes and lower 30-day mortality (eFigure 9 in the Supplement). Using recycled predictions across cohort years and patient-level analyses, we estimated that 57.3% (95% CI, 48.4%-69.9%) of the decrease in risk-adjusted mortality between 2003 and 2014 could be attributed to increased use of the 3 evidence-based care processes.
Discussion
In the national VHA health care system, we observed lower risk-adjusted mortality among patients with SAB when they received evidence-based care processes, including appropriate antibiotic therapy, echocardiography, and consultation with ID specialists. Moreover, there was evidence of a doseresponse relationship between the number of care processes that a patient received and mortality. On the basis of data from this cohort, we estimated that 57.3% of the decrease in riskadjusted mortality among patients with SAB between 2003 and 2014 could be attributed to increased use of these evidencebased care processes.
These results from 124 hospitals suggest that advances in care are driving decreases in mortality among patients with SAB, a common and serious infection. By 2014, crude mortality among patients with SAB in the VHA was 16.5%, which is lower than described in most published cohorts. [1] [2] [3] [4] 29 It is plausible that increasing use of appropriate antibiotic therapy and echocardiography contributed to decreasing mortality through more rapid clearance of infection and earlier identification of endocarditis. In addition, associations between echocardiography use and mortality could occur if echocardiography was also a marker for receipt of other beneficial procedures, such as control of infectious sources through removal of infected devices or abscess drainage. The mechanisms that link ID consultation to decreasing mortality are less obvious, but based on prior studies, 4, 11, 12 ID physicians likely optimize antibiotic prescribing and facilitate earlier identification and control of infectious sources. 
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Our results also indicate that opportunity remains for improvement in SAB outcomes through even greater use of evidence-based care processes. Although the use of evidencebased processes substantially improved during the study period, approximately half (47.8%) of patients did not receive all 3 processes in 2014. Assuming that some patients have contraindications to echocardiography and allergies to antibiotics, substantial opportunity for improvement in these care processes still likely remains. Evidence from a prior study 29 indicates that quality improvement programs can increase use of evidence-based care processes and improve outcomes for patients with SAB. In 12 hospitals in Spain, implementation of a quality improvement bundle, including use of appropriate antibiotic therapy, echocardiography, and early source control (eg, catheter removal, abscess drainage), led to a 5.6% absolute decrease (22.3% in the preintervention period to 16.7% in the postintervention period) in 30-day mortality. Given this evidence and the high prevalence of SAB, hospitals that do not routinely apply these evidence-based practices should prioritize quality improvement programs that address SAB management. In addition, our results support widespread tracking of quality measures based on these care processes to guide SAB quality improvement programs.
Our observation of decreasing mortality among patients with SAB must be considered in the context of prior studies 30, 31 that describe decreasing mortality among VHA patients hospitalized with other conditions, such as congestive heart failure and acute myocardial infarction. This finding raises the question of whether there may be secular trends in the VHA populations that are associated with a generalized improvement in hospital outcomes over time. We adjusted for factors potentially driving secular trends by adjusting at the patient level for cohort year and a wide range of patient characteristics, including demographic features, comorbidities, site of bacteremia onset, MRSA vs MSSA infection, and illness severity based on vital signs and laboratory studies. When models were stratified 
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Care process indicator variables were included individually in risk adjustment models with all variables in Table 2 . All variables in Table 2 by year, the associations between care processes and mortality were generally constant throughout the cohort years and were stronger in later years of the cohort. Models for associations between care processes and mortality also adjusted for cohort year to account for secular trends not captured by measured patient characteristics. Prior studies 30,31 that described decreasing mortality rates in VHA hospitals did not examine changes in specific care processes that may be driving decreases in mortality. Our study of SAB could help explain the decreasing risk-adjusted mortality among VHA patients through the use of disease-specific, evidence-based care processes. This large cohort study also adds to the prior literature on risk factors for mortality among patients with SAB. Results were generally similar to those previously reported in smaller cohorts, with higher mortality associated with increasing age, infection with MRSA compared with MSSA, selected comorbidities (eg, congestive heart failure, malignant tumors, and liver disease), and patient vital signs and laboratory values that indicate increased illness severity at bacteremia onset.
The incidences of HCA and HO bacteremia decreased in VHA hospitals between 2003 and 2014, whereas the incidence of CA bacteremia was stable. It is plausible that the decrease in HCA and HO infections was influenced by the VHA's bundled intervention to reduce HCA MRSA infections, which began in 2007.
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In contrast, one would not expect the interventions in the MRSA bundle to reduce rates of CA bacteremia.
Limitations
This study had limitations. As in any observational study, there is potential for unmeasured confounding. To fully explain our results, confounding factors would need to have affected associations between year of cohort entry and mortality, year of cohort entry and use of evidence-based care processes, and use of evidence-based care processes and mortality.
33, 34 We also relied on administrative data for diagnoses of comorbidities, which may be inaccurate and allow residual confounding.
35,36
In addition, we did not have detailed clinical data on sources of bacteremia, whether these sources were controlled, or presence of all sites of infection. Finally, most patients with SAB in VHA hospitals were men, limiting the generalizability of these findings to other populations.
Conclusions
We observed substantial increases in the use of evidencebased care processes for patients with SAB between 2003 and 2014 that were associated with a marked decrease in mortality. There is a need for continued implementation of quality improvement initiatives to increase the adoption of these evidence-based care processes for patients with SAB, supported by quality measures that reflect use of these processes. Table 2 ; ** All variables in Table 2 Table 2 ; ** All variables in Table 2 and three care processes were entered to the model simultaneously Table 2 Process Measures Adjusted OR [95% CI]*
